Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nissan Medical Industries Ltd (NISA.TA)
Tel Aviv, IL
Established in 1984 and based in Tel Aviv-Yafo, Israel, Nissan Medical Industries Ltd, operating through its subsidiary, specializes in the production and distribution of spunlace non-woven textiles. These materials find extensive application across diverse sectors, including reusable and disposable consumer items, medical supplies, automotive manufacturing, infrastructure development, and various hygiene products. The company's market reach encompasses the United States, Canada, Europe, and Israel, with product sales managed through its network of sales agents.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.19% | -2.91% | -12.65% | -21.77% | -26.09% | -17.89% | -29.94% | -14.56% | -76.07% | -84.44% | -0.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-1.9% Q4'25: +8.1% (vs Q4'24)
-
EPS growth Medical - Instruments & Supplies: +16.3%-76.8% Q4'25: +104.9% (vs Q4'24)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+2.9% ★ Q4'25: +8.2% (vs Q4'24)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+3.3% Q4'25: +4.4% (vs Q4'24)
-
ROIC Medical - Instruments & Supplies: +6.0%+3.9% Q4'25: +5.4% (vs Q4'24)
-
Share dilution Medical - Instruments & Supplies: +0.1%+127.1% Q4'25: +127.1% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×4.07× Q4'25: 4.66× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 3/5 | 1/5 | 2/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 2/5 | 3/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 2/5 | 3/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 2/5 | 3/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-05 | B | 3/5 | 2/5 | 2/5 | 3/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 2/5 | 2/5 | 3/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-01 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yeheskel Nissan | Chief Executive Officer, MD & Director | 2M | male |
| Ron Broshi | Vice President of Business Development & Products at Sfantak | 1M | male |
| Yael Peleg | Production Site Manager of Spantec's | 993.0K | female |
| Michael Schwartzman | Company Technologist | 978.0K | male |
| Yuval Bernshtein | Company Engineer | 912.0K | male |
| Moshe Zorea | Chief Financial Officer | 829.0K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NISA.TA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
